Cart
sales@molnova.com
YIR-821
CAS No. 1883372-91-5
YIR-821 ( YIR821 )
Catalog No. M12924 CAS No. 1883372-91-5
YIR-821 is a small-molecule CD4 mimic that acts as a highly potent HIV entry inhibitor with IC50 of 2.8 uM against YTA48P virus with no significant cytotoxicity (CC50>200 uM).
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 100MG | Get Quote | Get Quote |
|
| 200MG | Get Quote | Get Quote |
|
| 500MG | Get Quote | Get Quote |
|
| 1G | Get Quote | Get Quote |
|
Biological Information
-
Product NameYIR-821
-
NoteResearch use only, not for human use.
-
Brief DescriptionYIR-821 is a small-molecule CD4 mimic that acts as a highly potent HIV entry inhibitor with IC50 of 2.8 uM against YTA48P virus with no significant cytotoxicity (CC50>200 uM).
-
DescriptionYIR-821 is a small-molecule CD4 mimic that acts as a highly potent HIV entry inhibitor with IC50 of 2.8 uM against YTA48P virus with no significant cytotoxicity (CC50>200 uM); A useful lead compound for the further development of HIV-1 entry inhibitors and could potentially be useful for co-administration with neutralizing antibodies for the treatment of HIV infection and AIDS.
-
SynonymsYIR821
-
PathwayMicrobiology/Virology
-
TargetHIV
-
RecptorHIV
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number1883372-91-5
-
Formula Weight534.10
-
Molecular FormulaC26H40ClN7O3
-
Purity>98% (HPLC)
-
Solubility——
-
SMILES——
-
Chemical NameN1-(4-chlorophenyl)-N2-(1-(2-(5-guanidinopentanamido)ethyl)-1-azaspiro[5.5]undecan-4-yl)oxalamide
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Ohashi N, et al. ChemMedChem. 2016 Apr 19;11(8):940-6.
molnova catalog
related products
-
Cyclotriazadisulfona...
Cyclotriazadisulfonamide hydrochloride is a selective inhibitor of CD4-targeted HIV entry and inhibits the co-translational translocation of human CD4 into the ER lumen in a signal peptide-dependent way.
-
KNI-1657
KNI-1657 (KNI1657) is a highly potent HIV-1 protease inhibitor (97% inhibition at 1 nM) with high sensitivity against lopinavir/ritonavir- or darunavir-resistant strains.
-
Diphyllin
Diphyllin could be characterized as a new V-ATPase inhibitor in treating gastric cancer and inhibiting the phosphorylation of LRP6 in Wnt/β-catenin signaling.
